Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
NCT03270748
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
78
Enrollment
OTHER
Sponsor class
Conditions
Myeloid Malignancies
Interventions
DRUG:
GvHD prophylaxis
Sponsor
Gruppo Italiano Trapianto di Midollo Osseo